PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1405209-2	1992	Prazosin monotherapy resulted in a significant decrease in prolactin levels, followed by inhibited elaboration of luteinizing, follicle-stimulating, and testicular hormones in the first 6 months of therapy without changing estradiol levels.	Prazosin	0-8	prolactin	Homo sapiens	59-68	
8502593-4	1993	After 12 months of prazosin treatment basal and stimulated LH and prolactin secretion significantly decreased while estradiol secretion significantly increased.	Prazosin	19-27	prolactin	Homo sapiens	66-75	
8502593-9	1993	Long-term prazosin treatment shows an inhibitory effect on FSH and prolactin secretion but stimulatory one on estrogens secretion in male hypertensive patients.	Prazosin	10-18	prolactin	Homo sapiens	67-76	
1405209-3	1992	The hypoprolactinemic effect of prazosin was significantly enhanced with an increase in therapy duration and more profound in patients who had high baseline prolactin levels and in younger patients.	Prazosin	32-40	prolactin	Homo sapiens	8-17	
6102000-2	1980	Prazosin was followed by a rise in plasma glucose and serum free fatty acids (FFA) in both normal and diabetic subjects; there was a trend upward in serum albumin (IRI), but growth hormone (GH), prolactin (PRL), and gastrin did not change.	Prazosin	0-8	prolactin	Homo sapiens	206-209